Also known as: American Society for Clinical Oncology, ASCO
The FDA has cleared CStone Pharmaceuticals' investigational new drug application to begin a Phase II trial of its trispecific antibody CS2009 in advanced solid tumors. The multicenter trial will evaluate monotherapy and combination regimens across nine cancer types in Australia, China, and the U.S. Initial Phase I data showed a favorable safety profile and encouraging antitumor activity.
Novartis expands US radioligand manufacturing with new Texas and North Carolina facilities to bolster domestic production of cancer treatments. Telix Pharmaceuticals reports positive Phase 3 prostate cancer trial data and maintains 2026 revenue guidance of US$950-970 million.
A Cleveland Clinic study found no racial survival disparities in multiple myeloma when patients have equal access to modern therapies. Clinical cases demonstrate long-term remission with second stem cell transplants and targeted agents like daratumumab.
The FDA has accepted an NDA for iberdomide in combination with anti-CD38 antibodies for relapsed or refractory multiple myeloma. A phase 2 study reports a 39% near complete response rate for the DaraKPd quadruplet therapy with durable MRD negativity. Preclinical research shows the RXR agonist IRX4204 sensitizes myeloma cells to ferroptosis and enhances lenalidomide efficacy.
The FDA has accepted for review a New Drug Application for tirabrutinib, a Bruton tyrosine kinase inhibitor, for relapsed or refractory primary central nervous system lymphoma. The application is based on phase 2 PROSPECT trial data showing an overall response rate of 67% and complete response rate of 44%. The target action date is December 18, 2026.
An experimental pill called daraxonrasib nearly doubled survival for patients with advanced pancreatic cancer in a clinical trial, marking a significant advance for a deadly disease. The drug targets a mutated protein previously considered "undruggable" and reduced the risk of death by 60% compared to chemotherapy.
BioNTech presented phase 2 data for HER2-directed ADC Trastuzumab Pamirtecan showing 47.9% response rate in endometrial cancer, with FDA submission planned for 2026. BioLineRx dosed first patient in phase 1/2a GLIX1 trial for glioblastoma and reported new preclinical data. Both companies presented at ASCO 2026.
BMS's mezigdomide doubled progression-free survival in relapsed/refractory multiple myeloma at ASCO, while the FDA reviews iberdomide with a decision due by August 17. C4 Therapeutics has dosed the first patient in its Phase 2 MOMENTUM trial of cemsidomide.
BioNTech faces mixed analyst views as Bernstein initiates with a cautious Market Perform rating, while the company secures FDA Fast Track designation for BNT113 and prepares for a shareholder vote on capital restructuring and leadership transition.
The FDA has accepted the New Drug Application for giredestrant plus everolimus in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer. The filing is based on Phase III evERA data showing reduced risk of disease progression or death versus standard-of-care endocrine therapy plus everolimus.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06964009 |
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer |
RECRUITING | PHASE1 |
| NCT06907797 |
Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing |
RECRUITING | NA |
| NCT06895473 |
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome |
RECRUITING | PHASE2 |
| NCT06795139 |
Pilot of a Trial Enrollment Diversity Dashboard |
ACTIVE_NOT_RECRUITING | NA |
| NCT06582849 |
Enhanced Assistance During Radiotherapy for Unmet Essential Needs |
COMPLETED | NA |
| NCT06557512 |
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma |
RECRUITING | NA |
| NCT06469307 |
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE) |
RECRUITING | NA |
| NCT06377852 |
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study |
RECRUITING | PHASE3 |
| NCT06089083 |
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery |
RECRUITING | |
| NCT06046014 |
Feasibility of Expressive Writing for Body Image Distress and Anxiety Among Adolescent and Young Adult Cancer Survivors |
COMPLETED | NA |
